secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001628280-25-004197
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo reports updated Phase 1/2 STAAR data for ST-920; eGFR slope +3.061; FDA Accelerated Approval path confirmed
--------------------------------------------------------------------------------

- 33 patients treated; gene therapy ST-920 generally well-tolerated; no deaths or discontinuations.
- ERT-naïve/pseudo-naïve patients showed sustained α-Gal A activity up to 42 months; 17/18 ERT patients remain off ERT.
- 23 patients with ≥12 months follow-up: mean annualized eGFR slope +3.061 (95% CI 0.863-5.258), indicating potential kidney improvement.
- FDA agreed to Accelerated Approval using 52-week eGFR slope; BLA submission expected H2 2025.
- Significant QoL (SF-36 General Health +10.6, p=0.0020) and GI symptom improvements; anti-α-Gal A antibodies reduced/eliminated in 9/10 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828025004197/0001628280-25-004197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828025004197/sgmo-20250206.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-004197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer